Agency classClass IIOur severity:Moderate FDA (Drugs)·D-0664-2026·Announced 2026-07-15

Methohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide

QuVa Pharma is recalling Methohexital Sodium 100 mg/10 mL compounded drug vials due to failed impurities and degradation specifications. The recall affects multiple lot numbers distributed nationwide.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 2/5 (Moderate).

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: This is an FDA Class II recall. The source text specifies only failed impurities and degradation specifications with no reported illnesses or injuries, which qualifies as a moderate-severity precautionary recall.

Plain-English summary

QuVa Pharma, Inc. is recalling Methohexital Sodium 100 mg/10 mL (10 mg/mL), Rx only, a compounded drug product due to failed impurities and degradation specifications. The affected product is distributed nationwide within the United States.

The recall affects multiple lot numbers with expiration dates ranging from July 2026 through August 2026, including lots 10162261, 10162262, 10162279, 10162280, 10162314, 10162315, 10162465, 10162466, 10162491, 10162492, 10162542, 10162543, 10162559, 10162560, 10162623, 10162624, 10162693, 10162694, 10162735, 10162736, 10162753, 10162754, 10162772, 10162773, 10162791, 10162792, 10162810, 10162811, 10162820, 10162853, 10162854, 10163046, 10163156, and 10163157. The product code is 70092-1310-46.

Consumers and healthcare providers should discontinue use of the affected lots. For questions or additional information, contact QuVa Pharma, Inc. at 1075 W Park One Dr, Suite 100, Sugar Land, TX 77478.

The recalled product

Product: Methohexital Sodium, 100 mg/10 mL (10 mg/mL), Total Volume: 10 mL, Rx only, Compounded drug, QuVa Pharma, 1075 W Park One Dr, Suite 100, Sugar Land, TX 77478, Product code: 70092-1310-46.
Manufacturer: QuVa Pharma, Inc.
Category: Drug — Compounded Drug
Hazard: impurities
degradation

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (20)

Lot #: 10162261
10162262
10162279
10162280
Exp. Date 07/21/2026
10162314
10162315
Exp. Date 07/22/2026
10162465
10162466
10162491
10162492
Exp. Date 07/26/2026
10162542
10162543
Exp. Date 07/27/2026
10162559
10162560
Exp. Date 07/28/2026
10162623

Distribution

Distributed nationwide across the United States.

Same manufacturer · QuVa Pharma, Inc.

See all →

High
Compounded pain injection syringes recalled over presence of particulate matter
FDA (Drugs) · 2025-11-05
High
Compounded Fentanyl and Bupivacaine Epidural Injections Recalled for Sterility Assurance
FDA (Drugs) · 2025-04-02
High
Compounded Fentanyl-Bupivacaine Epidural Injections Recalled for Sterility Failure
FDA (Drugs) · 2025-04-02
High
Compounded Fentanyl-Ropivacaine Epidural Injection Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2025-04-02
High
Oxytocin injection recalled for incorrect sodium chloride concentration
FDA (Drugs) · 2022-10-05

Same hazard · impurities